Skip to main content
. Author manuscript; available in PMC: 2012 Sep 15.
Published in final edited form as: Cancer Res. 2011 Jul 20;71(18):5965–5975. doi: 10.1158/0008-5472.CAN-11-0445

Figure 4.

Figure 4

(A) The TIMM results from the p85 adaptor complexes in KRAS mutated A549, H460 and H23 NSCLC cells in the absence or presence of rapamycin (50 nM) for 16 hours. Results were quantified as in Figure 2. (B) Extracts from the A549 and H23 treated as in (A) were probed with the indicated antibodies. (C) H23 and A549 cells were transiently transfect with scramble, IRS1, or IRS2 siRNA. Cells were treated in the absence or presence of rapamycin (50 nM) for 16 hours. Cells were lysed and probed with the indicated antibodies.